Giuseppe Maria Ettorre1, Giovanni Battista Levi Sandri2, Andrea Laurenzi3, Marco Colasanti3, Roberto Luca Meniconi3, Raffaella Lionetti4, Roberto Santoro3, Pasquale Lepiane3, Rosa Sciuto5, Giuseppe Pizzi6, Roberto Cianni7, Rita Golfieri8, Gianpiero D'Offizi4, Adriano M Pellicelli9, Mario Antonini10, Giovanni Vennarecci3. 1. Division of General Surgery and Liver Transplantation, San Camillo Hospital, circ.ne Gianicolense 87, 00152, Rome, Italy. gmettorre@scamilloforlanini.rm.it. 2. Division of General Surgery and Liver Transplantation, San Camillo Hospital, circ.ne Gianicolense 87, 00152, Rome, Italy. gblevisandri@gmail.com. 3. Division of General Surgery and Liver Transplantation, San Camillo Hospital, circ.ne Gianicolense 87, 00152, Rome, Italy. 4. Division of Hepatology and Infectious Disease, National Institute for Infectious Disease "L. Spallanzani", via Portuense 292, 00152, Rome, Italy. 5. Division of Nuclear Medicine, IFO Regina Elena National Cancer Institute, via Elio Chianesi 53, 00100, Rome, Italy. 6. Division of Interventional Radiology, IFO Regina Elena National Cancer Institute, via Elio Chianesi 53, 00100, Rome, Italy. 7. Division of Interventional Radiology, S.M. Goretti Hospital, via Guido Reni, 04010, Latina, Italy. 8. Division of Radiology, S. Orsola-Malpighi Hospital, via Pietro Albertoni 15, 40138, Bologna, Italy. 9. Liver Unit, San Camillo Forlanini Hospital, circ.ne Gianicolense 87, 00152, Rome, Italy. 10. Anesthesiology and Intensive Care Unit, National Institute for Infectious Disease "L. Spallanzani", Rome, Italy.
Abstract
BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.
BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patientdeath was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.
Authors: Giuseppe Maria Ettorre; Roberto Santoro; Claudio Puoti; Rosa Sciuto; Livio Carpanese; Mario Antonini; Giorgio Antonucci; Carlo L Maini; Lucia Miglioresi; Giovanni Vennarecci Journal: Transplantation Date: 2010-10-27 Impact factor: 4.939
Authors: J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni Journal: Cancer Treat Rev Date: 2010-08-17 Impact factor: 12.111
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts Journal: Liver Transpl Date: 2005-12 Impact factor: 5.799
Authors: Laura E Moreno Luna; Paul Y Kwo; Lewis R Roberts; Teresa A Mettler; Denise N Gansen; James C Andrews; Gregory A Wiseman; Vijay Laxmi Misra Journal: Nat Rev Gastroenterol Hepatol Date: 2009-11 Impact factor: 46.802
Authors: Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2013-10-01 Impact factor: 17.425
Authors: Samer Tohme; Daniel Sukato; Hui-Wei Chen; Nikhil Amesur; Albert B Zajko; Abhinav Humar; David A Geller; James W Marsh; Allan Tsung Journal: J Vasc Interv Radiol Date: 2013-11 Impact factor: 3.464
Authors: Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Marco Colasanti; Edoardo De Werra; Gianluca Mascianà; Daniele Ferraro; Giovanni Tortorelli; Rosa Sciuto; Pierleone Lucatelli; Giuseppe Pizzi; Ubaldo Visco-Comandini; Giovanni Vennarecci Journal: Hepatobiliary Surg Nutr Date: 2017-02 Impact factor: 7.293
Authors: Michel Rayar; Giovanni Battista Levi Sandri; Marc Blondeau; Mohamed Lakehal; Véronique Desfourneaux; Laurent Sulpice; Bernard Meunier; Karim Boudjema Journal: Transl Gastroenterol Hepatol Date: 2018-05-02
Authors: Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Valerio Giannelli; Marco Colasanti; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Gianpiero D'Offizi; Mario Antonini; Giovanni Vennarecci; Pierleone Lucatelli Journal: Transl Gastroenterol Hepatol Date: 2017-11-27
Authors: Mohammad Elsayed; William Wagstaff; Keywan Behbahani; Alexander Villalobos; Zachary Bercu; Bill S Majdalany; Mehmet Akce; David M Schuster; Hui Mao; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2021-07-26 Impact factor: 2.740